Allergan to move into Phase III trials with depression drug that’s raising eyebrows
The Pharma Letter | April 07, 2017
Botox (onabotulinumtoxinA), a treatment which made its name for its aesthetic potential in reducing facial wrinkles, is to be taken into Phase III trials in major depressive disorder (MDD).